Article
Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.
Advances in biological regulation - 1 Jan 2021
Kuhn Natalia, Klinger Bertram, Uhlitz Florian, Sieber Anja, Rivera Maria, Klotz-Noack Kathleen, Fichtner Iduna, Hoffmann Jens, Blüthgen Nils, Falk Christine, Sers Christine, Schäfer Reinhold
Abstract excerpt
In colorectal cancer (CRC), the prevalence of NRAS mutations (5-9%) is inferior to that of KRAS mutations (40-50%). NRAS mutations feature lately during tumour progression and drive resistance to anti-EGFR therapy in KRAS wild-type tumours. To elucidate specific functions of NRAS mutations in CRC, we expressed doxycycline-inducible G12D and Q61K mutations in the CRC cell line Caco-2. A focused phospho-proteome...
Topics
Join the communities discussing this publication.